Overview

Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)

Status:
Withdrawn
Trial end date:
2018-12-31
Target enrollment:
Participant gender:
Summary
This is a single center, open-label study to evaluate the efficacy of AKCEA-ANGPTL3- LRX for reduction of low density lipoprotein cholesterol (LDL-C) levels in patients with Homozygous Familial Hypercholesterolemia (HoFH).
Phase:
Phase 2
Details
Lead Sponsor:
Akcea Therapeutics
Collaborator:
Ionis Pharmaceuticals, Inc.